Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

161.72 -0.92 (-0.57%)
Official Closing Price Updated: 7:00 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,178,879
Open 162.09
Bid (Size) 161.00 (2)
Ask (Size) 162.58 (1)
Prev. Close 162.64
Today's Range 161.14 - 163.69
52wk Range 130.96 - 182.89
Shares Outstanding N/A
Dividend Yield 3.66%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
7 Safe Haven Stocks That Can Withstand the Market’s Worst Meltdowns
Safe haven stocks offer stability even during market fall in communication, financials, healthcare, energy and consumer staples. 
Via InvestorPlace
Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher
After falling nearly 6% based on concerns about Humira sales, AbbVie stock is recovering, and bullish analyst sentiment is likely to push the stock higher 
Via MarketBeat

Performance

YTD
+1.19%
+1.19%
1 Month
-10.53%
-10.53%
3 Month
-1.63%
-1.63%
6 Month
+13.51%
+13.51%
1 Year
+6.66%
+6.66%

More News

Read More
Inflation-Proof Fortunes: 7 Dividend Aristocrats to Keep Your Wealth Growing
Via InvestorPlace
Topics Economy
Exposures Interest Rates
AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales
Via Investor's Business Daily
Peeling Back The Layers: Exploring AbbVie Through Analyst Insights
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
AbbVie's Options Frenzy: What You Need to Know
Via Benzinga
Better Dividend Stock: AbbVie or Johnson & Johnson?
Via The Motley Fool
3 Dividend Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
Via The Motley Fool
AbbVie (ABBV) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
Via Benzinga
Tech Stocks Rebound As Magnificent 7 Roar On Strong Earnings, Energy Giants Tumble: What's Driving Markets Friday?
Via Benzinga
Topics Economy
Exposures Interest Rates
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
Via Benzinga
AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title
Via Investor's Business Daily
Wall Street Futures Ride High On Microsoft, Alphabet Cheer, But Will Inflation Data Burst The Bubble? Why This Analyst Thinks Bull Run Isn't Over Yet
Via Benzinga
Topics Economy
Exposures Interest Rates
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
Via Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
Via InvestorPlace
Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes
Via InvestorPlace
Buying the Dip in These 3 Undervalued Dividend Stocks
Via The Motley Fool
3 Dividend Kings Down 11% You’ll Regret Not Buying on the Dip
Via InvestorPlace
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Via Benzinga
Why I Keep Buying This Ultra-High-Yielding ETF for Passive Income
Via The Motley Fool
Topics ETFs
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.